Physician profile
David A Green
NPI 1215926522
$5,463.97
in general payments reported to CMS, 2019-2025
53 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $158 · 2021: $253 · 2022: $599 · 2023: $1,671 · 2024: $1,655 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,515.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $949.28 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $436.88 | 2019-2024 | |
| Ucb, INC. | $266.11 | 2019-2024 | Briviact |
| Pfizer INC. | $214.35 | 2019-2024 | |
| Corium, LLC | $202.78 | 2022-2024 | Azstarys, Adlarity |
| Jazz Pharmaceuticals INC. | $194.82 | 2022-2025 | |
| Amgen INC. | $175.15 | 2019-2024 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $161.56 | 2019-2023 | Austedo Xr |
| Eisai INC. | $153.95 | 2019-2024 | |
| Lundbeck LLC | $147.92 | 2022-2024 | Vyepti |
| Tg Therapeutics, INC. | $147.32 | 2023-2025 | |
| Celgene Corporation | $145.33 | 2022-2024 | Zeposia |
| Genentech USA, INC. | $138.80 | 2019-2024 | Ocrevus, Enspryng |
| Livanova USA, INC. | $132.63 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $129.36 | 2019-2021 |
Show all 52 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.